Tags : Multiple Solid Tumors

Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100

Shots: The CodeBreaK 100 development program evaluates AMG 510 (proposed INN sotorasib, qd) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Eligible patients were heavily pretreated with at least 2L+ treatment and were enrolled four dose cohorts: 180 mg/360 mg/720 mg/960 mg This Phase 1 dose-escalation study evaluated 42 heavily pretreated […]Read More